Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

4D Molecular Therapeutics (FDMT) Asset Utilization Ratio: 2021-2025

Historic Asset Utilization Ratio for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to 0.00.

  • 4D Molecular Therapeutics' Asset Utilization Ratio rose 862.66% to 0.00 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.00, marking a year-over-year increase of 862.66%. This contributed to the annual value of 0.00 for FY2024, which is 99.88% down from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Asset Utilization Ratio stood at 0.00, which was up 300.80% from 0.00 recorded in Q2 2025.
  • 4D Molecular Therapeutics' Asset Utilization Ratio's 5-year high stood at 0.09 during Q2 2021, with a 5-year trough of 0.00 in Q3 2024.
  • Moreover, its 3-year median value for Asset Utilization Ratio was 0.01 (2023), whereas its average is 0.02.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Asset Utilization Ratio crashed by 99.95% in 2024, and later soared by 862.66% in 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Asset Utilization Ratio (Quarterly) stood at 0.06 in 2021, then tumbled by 80.99% to 0.01 in 2022, then spiked by 411.85% to 0.06 in 2023, then plummeted by 99.89% to 0.00 in 2024, then surged by 862.66% to 0.00 in 2025.
  • Its Asset Utilization Ratio was 0.00 in Q3 2025, compared to 0.00 in Q2 2025 and 0.00 in Q1 2025.